Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Biomaterials. 2020 Feb 21;241:119906. doi: 10.1016/j.biomaterials.2020.119906

Fig. 7. FerA domains directly interacted with AAV9.

Fig. 7.

Purified AAV9 was first incubated with hDys-FerA (A), hMyo-FerA (B), hOto-FerA (C), or mOto-FerA domain (D) for 2 h at 4 °C, then CaptureSelect™ biotin anti-AAV9 conjugate was added into the complex for another 1 h at RT, followed by Streptavidin C1 beads-based pull down assays and immunoblotting analysis with indicated ferlin antibodies. Meanwhile, the incubated complexes of AAV9 with Streptavidin C1 beads, Streptavidin C1 beads with FerA domains, AAV9 and FerA domains with C1 beads, and the biotin anti-AAV9 conjugate and FerA domains with C1 beads were separately included as controls. sc: streptavidin C1 beads, 9: AAV9, B: biotin anti-AAV9 conjugate, hDF: hDys-FerA, hMF: hMyo-FerA, hOF: hOto-FerA, mOF: mOto-FerA. IB: immunoblot. (E) Immunoblot using B1 and dysferlin antibodies of pull down assay in which biotin-GFP-hDys-FerA protein was incubated with AAV9, followed by addition of Streptavidin C1 beads for 0.5 h at RT. IB: immunoblot.